TWI786777B - Sarm1之抑制劑 - Google Patents

Sarm1之抑制劑 Download PDF

Info

Publication number
TWI786777B
TWI786777B TW110130799A TW110130799A TWI786777B TW I786777 B TWI786777 B TW I786777B TW 110130799 A TW110130799 A TW 110130799A TW 110130799 A TW110130799 A TW 110130799A TW I786777 B TWI786777 B TW I786777B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
chiral
mmol
Prior art date
Application number
TW110130799A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214597A (zh
Inventor
陶德 波薩納克
拉杰什 德芙拉吉
羅伯特 歐文 修斯
安德鲁 布雷利
派克 理查 安德魯 傑瑞斯
雪莉 安妮 帕勒特
Original Assignee
美商達薩瑪治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商達薩瑪治療公司 filed Critical 美商達薩瑪治療公司
Publication of TW202214597A publication Critical patent/TW202214597A/zh
Application granted granted Critical
Publication of TWI786777B publication Critical patent/TWI786777B/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110130799A 2020-08-24 2021-08-20 Sarm1之抑制劑 TWI786777B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US63/069,408 2020-08-24
US202163142398P 2021-01-27 2021-01-27
US63/142,398 2021-01-27

Publications (2)

Publication Number Publication Date
TW202214597A TW202214597A (zh) 2022-04-16
TWI786777B true TWI786777B (zh) 2022-12-11

Family

ID=77775005

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110130799A TWI786777B (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑
TW111144632A TW202334117A (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111144632A TW202334117A (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑

Country Status (18)

Country Link
US (2) US12043613B2 (cg-RX-API-DMAC7.html)
EP (1) EP4200293A1 (cg-RX-API-DMAC7.html)
JP (2) JP7349046B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230057396A (cg-RX-API-DMAC7.html)
AU (2) AU2021333558C1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002575A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189181A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000525A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230113A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000038A (cg-RX-API-DMAC7.html)
EC (1) ECSP23012981A (cg-RX-API-DMAC7.html)
IL (1) IL300586A (cg-RX-API-DMAC7.html)
MX (1) MX2023002256A (cg-RX-API-DMAC7.html)
PE (1) PE20230737A1 (cg-RX-API-DMAC7.html)
TW (2) TWI786777B (cg-RX-API-DMAC7.html)
WO (1) WO2022046606A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202301801B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
CA3226869A1 (en) 2021-07-28 2023-02-02 Rao Kolluri Substituted pyridine derivatives as sarm1 inhibitors
KR20250040698A (ko) * 2022-07-21 2025-03-24 아밀릭스 파마슈티컬스, 인코포레이티드 올리고뉴클레오티드 조성물 및 이의 방법
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
EP4655069A1 (en) 2023-01-24 2025-12-03 Disarm Therapeutics, Inc. Pyridazines as sarm1 inhibitors
WO2024222835A1 (en) * 2023-04-27 2024-10-31 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025049184A1 (en) 2023-08-25 2025-03-06 Eli Lilly And Company (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
WO2025045746A1 (en) * 2023-08-25 2025-03-06 F. Hoffmann-La Roche Ag Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025157895A1 (en) 2024-01-25 2025-07-31 UCB Biopharma SRL Pyrrolidinone derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114662A1 (de) * 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
CA2504320A1 (en) 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
AU2003300099A1 (en) 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
KR20070095952A (ko) 2004-12-16 2007-10-01 버텍스 파마슈티칼스 인코포레이티드 염증성 질환, 증식성 질환 및 면역학적으로 매개된 질환치료용 Tec 계열 단백질 키나제의 억제제로서 유용한피리드-2-온
AU2007265965B2 (en) 2006-06-28 2012-03-08 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
EP2069333A1 (en) 2006-09-21 2009-06-17 Novartis Ag Pyrrole derivatives useful for the treatment of cytokine-mediated diseases
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
US20120328629A1 (en) 2011-06-24 2012-12-27 University Of Miami Therapeutic Applications Targeting SARM1
JP6482466B2 (ja) 2012-11-03 2019-03-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害剤
WO2014099694A1 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
EP3076789A4 (en) 2013-12-04 2017-11-22 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
EP3500285B1 (en) 2016-08-16 2022-04-20 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
WO2018057989A1 (en) 2016-09-24 2018-03-29 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
US20180251431A1 (en) 2016-12-09 2018-09-06 Vertex Pharmaceuticals Incorporated 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels
JP2020504115A (ja) 2016-12-22 2020-02-06 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換アゾリルピロロンおよびアゾリルヒダントインならびにその塩ならびに除草活性物質としてのその使用
CA3085460A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
EP3801500B1 (en) 2018-06-07 2025-03-05 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3801499B1 (en) 2018-06-07 2024-02-28 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2020158762A1 (ja) * 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
JP7289375B2 (ja) 2019-06-06 2023-06-09 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
WO2020252229A2 (en) 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
BR112022000354A2 (pt) 2019-07-22 2022-05-10 Bayer Ag Pirazóis e trizóis substituídos com amino na posição 5 como pesticidas
US12441719B2 (en) 2019-09-12 2025-10-14 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN114845709B (zh) 2019-11-05 2024-10-01 德米拉公司 用于治疗炎性病症的mrgprx2拮抗剂
CR20220375A (es) 2020-01-07 2022-09-22 Disarm Therapeutics Inc Inhibidores de sarm1
JP7478252B2 (ja) 2020-04-09 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
JP7477642B2 (ja) 2020-04-09 2024-05-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114662A1 (de) * 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Also Published As

Publication number Publication date
TW202334117A (zh) 2023-09-01
MX2023002256A (es) 2023-03-17
KR20230057396A (ko) 2023-04-28
PE20230737A1 (es) 2023-05-03
JP2023535236A (ja) 2023-08-16
TW202214597A (zh) 2022-04-16
JP2024016014A (ja) 2024-02-06
TW202530197A (zh) 2025-08-01
AU2024203373A1 (en) 2024-06-13
DOP2023000038A (es) 2023-03-15
AU2021333558C1 (en) 2024-06-20
BR112023002575A2 (pt) 2023-03-07
ECSP23012981A (es) 2023-03-31
CO2023001975A2 (es) 2023-03-07
JP7756130B2 (ja) 2025-10-17
US20220056013A1 (en) 2022-02-24
CA3189181A1 (en) 2022-03-03
CR20230113A (es) 2023-04-14
CL2023000525A1 (es) 2023-09-15
JP7349046B2 (ja) 2023-09-21
IL300586A (en) 2023-04-01
EP4200293A1 (en) 2023-06-28
AU2021333558B2 (en) 2024-02-22
WO2022046606A1 (en) 2022-03-03
ZA202301801B (en) 2024-09-25
US12043613B2 (en) 2024-07-23
US20240376083A1 (en) 2024-11-14
AU2021333558A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
TWI786777B (zh) Sarm1之抑制劑
CN115175900B (zh) Sarm1的抑制剂
CN114728007B (zh) Sarm1的抑制剂
JP7319395B2 (ja) Sarm1の阻害剤
CN116075511B (zh) 作为sarm1抑制剂的稠合吡唑衍生物
CN116568678B (zh) Sarm1的苯并吡唑抑制剂
CN115916764B (zh) 作为sarm1抑制剂的吲唑衍生物
JP2022534544A (ja) Sarm1の阻害剤
JP2020514361A (ja) 9,10,11,12−テトラヒドロ−8h−[1,4]ジアゼピノ[5’,6’:4,5]チエノ[3,2−f]キノリン−8−オン化合物およびその使用
TWI904906B (zh) Sarm1之抑制劑
HK40075925A (en) Inhibitors of sarm1
EA048703B1 (ru) Ингибиторы sarm1
BR122025022748A2 (pt) Inibidores de sarm1, composições que os compreendem, usos dos mesmos, métodos para inibir sarm1, e combinações
CN116940569A (zh) Sarm1抑制剂